IP Library Granted Patent US 8,017,804
Granted Patent B2
US 8,017,804 · App. 11/579,700 · Granted Sep 13, 2011

Lipids, lipid complexes and use thereof

Assignee: Silence Therapeutics AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,804
App. No.
11/579,700
Granted
Sep 13, 2011
Kind
B2
Abstract

The present invention is related to a compound according to formula (I), wherein R 1 and R 2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R 3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and YÉ is a pharmaceutically acceptable anion.

Claims (16)

1. A compound according to formula (I),

wherein R 1 and R 2 are each and independently selected from the group consisting of alkyl;

n is any integer between 1 and 4;

R 3 is an acyl selected from the group consisting of lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II),

wherein m is any integer from 1 to 3 and

Y − is a pharmaceutically acceptable anion.

2. The compound according to claim 1 , wherein R 1 and R 2 are each and independently selected from the group consisting of lauryl, myristyl, palmityl and oleyl.

3. The compound according to claim 1 , wherein R 1 is lauryl and R 2 is myristyl; or

R 1 is palmityl and R 2 is oleyl.

4. The compound according to claim 1 , wherein m is 1 or 2.

5. The compound according to claim 1 , wherein the compound is a cationic lipid.

6. The compound according to claim 1 , wherein Y − is selected from the group consisting of halogenids, acetate and trifluoroacetate.

7. The compound according to claim 1 , wherein the compound is selected from the group consisting of:

β-arginyl-2,3-diamino propionic acid-N-palmityl-N-oleyl-amide trihydrochloride

β-arginyl-2,3-diamino propionic acid-N-lauryl-N-myristyl-amide trihydrochloride

ε-arginyl-lysine-N-lauryl-N-myristyl-amide trihydrochloride

Assignments (2)
CHANGE OF NAME Recorded Jan 15, 2015
From: SILENCE THERAPEUTICS AG
To: SILENCE THERAPEUTICS GMBH
Reel/Frame 034767/0324 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2008
From: KEIL, OLIVER; KAUFMANN, JORG
To: SILENCE THERAPEUTICS AG
Reel/Frame 020990/0018 →
Priority Claims (2)
EP 04010700 · May 5, 2004 · regional
EP 04030847 · Dec 27, 2004 · regional
Continuity (1)
Related Publication 20080274116A1 · Nov 6, 2008